Hi gsuk, Thanks for your message. Yes, there a

Hi gsuk,

Thanks for your message. Yes, there are some potential upcoming revenue opportunities outside of the United States that are not COVID-based.

However, Samsung is owed $27 million dollars and the bill needs to be paid by December 31, 2020. I don't see any way that kind of revenue can be generated by ex-US HIV sales in the next 2 months -- and that assumes an immediate, no delay approval (which won't happen).

CytoDyn will also not receive a milestone from Vyera, as they are only the commercialization partner for HIV indications within the United States.

I suppose CytoDyn might be talking to the 11 Big Pharma companies regarding HIV commercialization agreements outside of the US. Interestingly, we were told today that those discussions were not associated with COVID.

If that's the case, there may be some milestone payments due upon BLA approval in various countries. But that assumes quite a number of complicated pieces need to fall into place within two months.

So, I am excited that we are mining these ex-US countries -- both with HIV and COVID indications. However, absent milestone payments for ex-US countries, I don't think there's any possibility that revenue can ramp up fast enough to provide the funds necessary to pay the Samsung bill.